Общество Объединение HIV.LV+371 26062077 (ежедневно 9 - 21)


Обязались править ДНК без последствий для потомков
увидеть комментарии (0)


See full article: «The Alliance for Regenerative Medicine Releases Statement of Principles on Genome Editing» | https://alliancerm.org/press-release/the-alliance-for-regenerative-medicine-releases-statement-of-principles-on-genome-editing/ |
The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, today released a Therapeutic Developers’ Statement of Principles, setting forth a bioethical framework for the use of gene editing in therapeutic applications.
The statement, developed by ARM’s Gene Editing Task Force and signed by 13 therapeutic developers using gene editing technologies, specifies five key principles for the ethical use of gene editing and genetic modification. This technology, in which DNA is inserted, replaced, removed, or modified at particular locations in the human genome, has the potential to provide a durable or curative effect for patients suffering from a wide variety of serious or potentially fatal genetic disorders. The Statement of Principles has been developed to provide a public perspective from industry on the use these technologies.
The principles stated in the document are:
1. We endorse investigation of therapeutic applications of somatic cell gene editing: Regulated, clinical validation of somatic cell-based gene editing technologies for non-inherited genetic modification is, and should remain, the primary objective of the therapeutic development community and, in contrast to germline gene editing, offers the most acceptable near-term path to potentially transformative therapeutic benefits for patients.
2. We support the use of gene editing standards to facilitate the development of safe and efficacious gene editing therapies: We recognize and support the ongoing work of the NIST Genome Editing Consortium, US Pharmacopeia, International Organization for Standardization (ISO), and other recognized standards development organizations to formulate gene editing standards that address key concepts such as off-target effects and their impact on tumor suppressors and oncogenes as well as the measurement and monitoring of genetic mosaicism.
3. We call for the continued evolution of national and regional regulatory frameworks governing the development of somatic cell gene editing techniques: We believe that evolving national and regional regulatory frameworks are important to support appropriate development of these technologies and should act as the primary regulatory and enforcement mechanism. It is our belief that arbitrary and ancillary oversight bodies or processes may carry the risk of delaying research and development efforts, which in turn would adversely impact afflicted patient populations.
4. We assert that germline gene editing is currently inappropriate in human clinical settings: We, as therapeutic developers utilizing gene editing technologies, are not modifying human germline cells for use in human clinical studies. Gene editing technologies have not matured to the point where human trials of edited germline cells are appropriate. Many important safety, ethical, legal, and societal issues involved with this type of gene editing remain unresolved.
5. Common commitment: Unless and until ethical and potential safety questions with respect to germline gene editing are adequately addressed, we do not support or condone germline gene editing in human clinical trials or for human implantation. We believe that these are international concerns and would be supportive of an effort to discuss therapeutic gene editing issues on a global stage.


atstāj tukšu: atstāj tukšu:

введите предохранительный код: